Amgen says it has completed construction of its first ‘next-generation’ biomanufacturing facility, located in Singapore.

The facility, in the Tuas district, “encompasses multiple technologies to enable greater speed, productivity and flexibility in commercial-scale manufacturing,” Amgen notes. It was built in less than two years, half the time required for conventional biomanufacturing plants.

Amgen chief executive Robert Bradway said “we are reinventing what it means to manufacture biologic medicines and Singapore is an ideal place to invest in such a pioneering facility”. He praised the state’s “talented workforce and commitment to the biotechnology industry”.

The biotech major also noted that it will continue building at the Tuas site and soon break ground on another facility where it will make the multiple myeloma drug Kyprolis (carfilzomib).